Johnson & Johnson just got a head start over Pfizer and Astellas in nonmetastatic prostate cancer. J&J’s new drug apalutamide won FDA approval Wednesday, months ahead of schedule, and it’s now ready to scoop up market share before its rivals win a new, similar approval for their treatment, Xtandi.Original Article
FDA gives Johnson & Johnson’s Erleada a quick push over the finish line with first-ever nonmetastatic prostate cancer nod
